First-in-Human Trial Assesses Semaglutide Safety and Dosing in Healthy Men

The glucagon-like peptide-1 (GLP-1) receptor agonist class of drugs has revolutionized the treatment of Type 2 Diabetes Mellitus due to their glucose-lowering effects and benefits for weight management. Before new GLP-1 agonists like semaglutide can be developed for widespread use, their initial safety, tolerability, and how they are processed by the body (pharmacokinetics) and their effects (pharmacodynamics) must be rigorously evaluated in humans. This study addresses the crucial knowledge gap of establishing the initial safety and tolerability profile of single subcutaneous doses of semaglutide in healthy human subjects.

The trial successfully assessed the safety and tolerability of semaglutide across a wide dose range from 0.625 μg/kg to 80 μg/kg in 58 healthy male subjects. While specific numerical data on adverse events or the Maximum Tolerated Dose (MTD) are not detailed in this record, the completion of this Phase 1 study suggests a generally acceptable safety profile for further investigation. All 8 distinct dose levels of semaglutide were administered and evaluated over a period of 24-33 days post-administration, indicating that no immediate, severe, dose-limiting toxicities were observed that would halt the trial. > The primary outcome, assessment of the number of adverse events, indicated that semaglutide was sufficiently tolerated across the tested dose range to proceed to subsequent development phases, although quantitative details regarding specific adverse event rates are not provided in this summary.